; and (2) the potential benefits of the use of opioid agonists or partial agonists for affected individuals. (b) Report Not later than one year after the date of enactment of the STOP Fentanyl Overdoses Act of 2023 , the Secretary shall submit a report to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, including the following data: (1) The number of people reached by educational materials funded pursuant to this section. (2) The geographic areas where people received such educational materials. (3) The remaining populations and areas targeted for awareness of educational materials, including the characteristics of such populations and areas such as the type of stakeholder and geographic area. (4) The select outcomes of education funded pursuant to this section as determined by the Secretary. . 302. Study on naloxone access (a) In general The Comptroller General of the United States shall conduct a study on actions that may be taken to ensure appropriate access and affordability of naloxone for individuals seeking to purchase naloxone. Such study shall address what is known about— (1) coverage of naloxone (in any available form), including whether naloxone can be covered as an over-the-counter drug under a group health plan or group or individual health insurance coverage (as such terms are defined in section 2791 of the Public Health Service Act ( 42 U.S.C. 300gg–91 )) or for individuals entitled to benefits under part A or enrolled under part B of title XVIII of the Social Security Act ( 42 U.S.C. 1395 et seq. ) or receiving medical assistance under a State plan under title XIX of such Act ( 42 U.S.C. 1396 et seq. ) or a waiver of such plan; (2) the out-of-pocket cost to consumers purchasing naloxone— (A) with a prescription, with and without coverage under any such plan or coverage; (B) over-the-counter, with and without coverage under any such plan or coverage; and (C) pursuant to a standing order